The largest clinical trial evaluating the new class of diabetes treatment has shown that Farxigy AstraZeneca can prevent heart and kidney risks in a wide range of patients, according to Reuters.
However, a drug belonging to a class of treatment known as SGLT2 inhibitors did not show a statistically significant benefit in the prevention of cardiac or cerebrovascular events or in patients with diagnosed cardiovascular disease. Diabetics have an increased risk of heart problems, making cardiovascular medications useful to doctors and patients.
Stephen Wiviott of Brigham and Boston Women's Hospital, the chief investigator in this cynical study, said these findings are important to provide a clear picture of SGLT2 drugs that have been addressed to diagnosed body patients so far. AstraZeneca hopes that new data will help extend the use of Farxiga in a wider range of patients. The main results of a study of a study conducted in a cohort of 17,000 patients were first reported in September, but details were revealed on Saturday at the Annual Meeting of the American Heart Association and published at the same time in the New England Journal of Medicine,
These results have shown that Farxiga reduces the risk of hospitalization due to heart disease by 27%, as well as the risk of kidney disease. While two smaller studies involving competing drug SGLT2 focused on patients with diagnosed heart disease, Wiviott said the overall picture of the study showed that the primary benefit was extensive infarct prevention. "When we analyze three studies, it is clear that the primary benefit of this class of cardiovascular drugs is to reduce heart failure," Wiviott said.
For decades, diabetologists have focused primarily on lowering blood glucose levels at certain levels. But the predisposition of diabetics to other issues such as heart failure, where survival is only 50%, shows that a holistic approach is needed, Wiviott says. "Right now, there is a message that lowering glucose levels may be as important as the ratio we are doing." We should choose medicines that improve patients' expected lifespan, not just medications that are effective in lowering blood glucose levels, "he said doctor.
Farxiga competes with competing pharmaceuticals SGLT2, including Jardiance, manufactured by Eli Lilly and Boehringer Ingelheim and Invokana Johnson & Johnson, who have already demonstrated increased life expectancy of patients with diagnosed heart problems, called Secondary Prevention. Since the AstraZeneca study also evaluated patients without diagnosed cardiovascular disease, this study opens up a wider market that includes primary prevention. The Declare study found no increased risk of amputations, fractures, bladder cancer or gangrene in patients treated with Farxiga, problems that were occasionally observed in SGLT-treated patients but increased genital infections.